Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Short summary

An 8-week treatment of ledipasvir-sofosbuvir achieved a 94% sustained virologic response rate in previously untreated HCV genotype 1 patients without cirrhosis, demonstrating noninferiority to a 12-week regimen and showing no additional benefit from ribavirin.

AI-generated from the title and abstract; the full text is not read.